CAPUTO, ANTONELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.802
EU - Europa 639
AS - Asia 538
OC - Oceania 4
AF - Africa 3
SA - Sud America 1
Totale 7.987
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.794
CN - Cina 296
SG - Singapore 210
FI - Finlandia 142
DE - Germania 105
UA - Ucraina 101
SE - Svezia 83
FR - Francia 77
IT - Italia 56
GB - Regno Unito 45
VN - Vietnam 14
CA - Canada 8
IE - Irlanda 7
GR - Grecia 6
IN - India 5
TR - Turchia 5
BE - Belgio 3
BG - Bulgaria 3
HK - Hong Kong 3
AT - Austria 2
AU - Australia 2
IL - Israele 2
NL - Olanda 2
NZ - Nuova Zelanda 2
BR - Brasile 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ES - Italia 1
HR - Croazia 1
HU - Ungheria 1
JP - Giappone 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MA - Marocco 1
MY - Malesia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 7.987
Salva come PNG Salva come JPEG
Città #
Fairfield 884
Woodbridge 813
Houston 754
Ann Arbor 675
Jacksonville 489
Ashburn 424
Santa Clara 423
Wilmington 332
Seattle 330
Cambridge 313
Chandler 273
Princeton 196
Singapore 163
Boardman 154
San Diego 112
Medford 53
Nanjing 53
Beijing 50
Helsinki 39
Des Moines 33
Roxbury 26
Hebei 25
Guangzhou 23
Shenyang 19
Changsha 17
Norwalk 17
Jiaxing 15
Nanchang 15
New York 13
Padova 13
Dong Ket 12
Ogden 9
London 8
Milan 8
Tianjin 8
Zhengzhou 8
Indiana 7
San Francisco 7
Dublin 6
Rome 6
Falls Church 5
Kunming 5
Wandsworth 5
Yenibosna 5
Jinan 4
Kharkiv 4
Los Angeles 4
Abano Terme 3
Brussels 3
Hefei 3
Mestre 3
Pune 3
Rimini 3
Sofia 3
Borås 2
Chions 2
Fuzhou 2
Haikou 2
Ho Chi Minh City 2
Hong Kong 2
Kilburn 2
Paris 2
Prescot 2
Redmond 2
Rubano 2
Southwark 2
Stockholm 2
Sydney 2
Tel Aviv 2
Toronto 2
Vienna 2
Acton 1
Atlanta 1
Auburn Hills 1
Auckland 1
Barcelona 1
Bengaluru 1
Berlin 1
Birmingham 1
Bologna 1
Bratislava 1
Budapest 1
Burlington 1
Campodarsego 1
Chiswick 1
Cimadolmo 1
Colombo 1
Crotone 1
Créteil 1
Dallas 1
Denton 1
Denver 1
Detroit 1
Dundalk 1
Edinburgh 1
Falkenstein 1
Ferrara di Monte Baldo 1
Frankfurt am Main 1
Geislingen an der Steige 1
Groningen 1
Totale 6.941
Salva come PNG Salva come JPEG
Nome #
Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide. 133
Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice. 128
Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL 119
Biocompatible Anionic Polymeric Microspheres as Priming Delivery System for Effetive HIV/AIDS Tat-Based Vaccines 119
The Sp1 transcription factor does not directly interact with the HIV-1 Tat protein 118
Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. 114
Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication 112
Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules. 112
Adenovirus type 12 early region 1A proteins repress class I HLA expression in transformed human cells. 112
HIV-1 Tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity 111
Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse. 108
Dystrophin restoration in skeletal, heart and skin arrector pili smooth muscle of mdx mice by ZM2 NP-AON complexes. 106
Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. 104
Control of SHIV-89.6p infection of cynomolgus monkeys by the HIV-1 tat protein vaccine 103
Characterization of immune responses elicited in mice by intranasal co immunization with HIV-1 Tat, gp140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. 103
Hpv-specific systemic antibody responses and memory b cells are independently maintained up to 6 years and in a vaccine-specific manner following immunization with cervarix and gardasil in adolescent and young adult women in vaccination programs in Italy 101
The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells 99
Cooperation in oncogenesis between BK virus early region gene and the activated human c-Harvey ras oncogene. 98
Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P) 98
Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. 97
Co-operation in cell transformation between BK virus and the human c-Harvey-ras oncogene. 97
Oncogenity of BK virus for immunosuppressed hamsters. 97
Interaction of Sp1 transcription factor with HIV-1 Tatprotein: looking for cellular partners. 96
Transactivation of BKV and SV40 early promoters by BKV and SV40 T-antigens. 96
HIV-1 Tat-based vaccines: from basic science to clinical trials 94
Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1 infected patients 94
Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which requires binding of Tat to viral particles. 93
Pentosan polysulfate as inhibitor of extracellular HIV-1 Tat 92
Tat-expressing Jurkat cells show an increased resistance to different apoptotic stimuli, including acute human immunodeficiency virus-type 1 (HIV-1) infection. 92
Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application 91
Transformation of human embryonic fibroblasts by BK virus, BK virus DNA and a subgenomic BK virus DNA fragment. 91
Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection 91
BK virus-plasmid expression vector that persists episomally in human cells and shuttles into Escherichia coli. 90
Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application 89
HIV-1 Tat affects the programming and functionality of human CD8+ T cells by modulating the expression of T-box transcription factors. 89
Episomal DNA of a BK virus variant in a human insulinoma. 88
New BK virus episomal vector for complementary DNA expression in human cells. 88
Recent advances in the development of HIV-1 Tat-based vaccines 87
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines 85
HIV-1 Tat-Based Vaccines: An Overview and Perspectives in the Field of HIV/AIDS Vaccine Development. 84
Prevalence of liver tumours in HIV-1 tat-transgenic mice treated with urethane 84
The systemic administration of a low dose of 20MePS-AON combined with novel cationic polymethylmethacrylate nanoparticles induces the rescue of dystrophin expression in the mdx murine model 83
Expression of hepatitis B surface antigen in human cells by a recombinant BK virus DNA vector. 83
Transcription pattern of the K3 open reading frame of HHV8 in primary effusion lymphoma and Kaposi's sarcoma 82
Increased excitability in tat-transgenic mice: Role of tat in HIV-related neurological disorders. 81
Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243). 81
Characterization of the effects of two polysulfonated distamycin A derivatives, PNU145156 and PNU 153429, on HIV type 1 Tat protein 80
The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccines against AIDS. 79
Problems and emerging approaches in HIV/AIDS vaccine development. 79
The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses. 78
Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. 78
Morphological, histochemical, immunohistochemical and ultrastuctural characterization of tumors and dysplastic and non-neoplastic lesions arising in BK virus/tat transgenic mice 77
Preparation and Characterization of Innovative Protein-coated Poly(Methylmethacrylate) Core-shell Nanoparticles for Vaccine Purposes 77
Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region 75
Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene 75
Reexamination of the coding potential of the HTLV-1 pX region. 74
Formation of oligomeric free BK virus DNA is required for tandem integration of viral genomes into cellular DNA. 74
The HIV-1 regulatory genes tat and rev as targets for gene therapy. 74
Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination. 73
High expression of exogenous cDNAs directed by HIV-1 long terminal repeat in human cells constitutively producing HIV-1 tat and adenovirus E1A/E1B. 73
Transcriptional silencing of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by the Krüppel-associated box repressor domain targeted to the transactivating response element. 72
Inhibition of HIV-1 Tat activity correlates with down-regulation of bcl-2 and results in reduction of angiogenesis and oncogenicity. 71
The HIV-1 Tat protein affects human CD4+ T-cell programing and activation, and favors the differentiation of naïve CD4+ T cells. 71
MULTIPLE FUNCTIONS OF IMMUNODEFICIENCY VIRUS TYPE 1 TAT PROTEIN IN THE PATHOGENESIS OF AIDS. 70
DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune response and strongly enhance cellular responses of HIV-1 tat DNA vaccination. 70
Transformation of hamster kidney cells by fragments of BK virus DNA 69
Reciprocal in vitro interactions between human herpesvirus-6 and HIV-1 Tat. 68
An Attenuated Herpes Simplex Virus Type 1 (HSV1) Encoding the HIV-1 Tat Protein Protects Mice from a Deadly Mucosal HSV1 Challenge 68
Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein. 65
Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi’s sarcoma via induction of basic fibroblast growth factor and the αvβ3 integrin 64
The presence of anti-Tat antibodies is predictive of long-term non-progression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters 64
Transcellular transactivation by the human immunodeficiency virus type 1 tat protein. 64
Nanoparticles for delivery of a pharmacologically active agent (United Kingdom Patent application) 62
Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env. 62
Transiently transfected and stably integrated HIV-1 provirus responds differentially to the silencing activity of the Kruppel-associated box (KRAB) 59
Induction of malignant subcutaneous sarcomas in hamsters by a recombinant DNA containing BK virus early region and the activated human c-Harvey-ras oncogene. 59
The increase in intra-macrophage thiols induced by new pro-GSH molecules directs the Th1 skewing in ovalbumin immunized mice. 59
Effect of tat transdominant negative mutants on HIV-1 replication in Jurkat T cell lines. 59
DNA immunization with HIV-1 tat mutated in the transactivation domain induces humoral and cellular immune response against wild-type Tat. 59
Functional polymeric nano/microparticles for protein and DNA vaccine delivery. 58
Protein friendly core-shell microspheres by dispersion polymerization as promising delivery systems for proteins 57
SHIV89.6P pathogencity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine 56
Constitutive expression of HIV-1 tat protein in human Jurkat T cells using a BK virus vector. 56
Recombinant Herpes Simplex Virus and uses therefor (United Kingdom Patent application) 55
The exogenous transactivation activity of HIV-1 tat. 55
HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection 54
The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. 54
Tumor-host interaction mediates the regression of BK virus-induced vascular tumors in mice: involvement of transforming growth factor-beta1 52
The tat gene and protein of the human immunodeficiency virus type 1. 51
Micellar-type complexes of taylor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. 50
Complex associates of plasmid DNA and novel class of block copolymers with poly(ethylene glycol)and cationic segments as new vectors for gene delivery 50
Vaccines (United Kingdom Patent application) 49
Sequence conservation and antibody cross-recognition of the clade B HIV-1 Tat protein vaccine candidate in HIV-1-infected Italian, Ugandan and Soth African individuals 49
Viral Vaccines 47
Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers greatly enhances the CTL response against Tat 44
Factors affecting amplification of BK virus episomal vectors in human cells. Brief report. 43
Long term protection against SHIV89.6P replication in Tat protein or tat DNA vaccinated cynomolgus monkeys upon tetanus toxoid boost and correlation with Tat immune response 43
Antiangiogenic, antitumoral and antimetastatic effects of two dystamicyn derivatives with anti-HIV-1 tat activity in a Kaposi's Sarcoma-like murine model 42
Development of HIV/AIDS vaccine based on Tat: preclinical and clinical studies. 40
Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine 40
Totale 7.859
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.780
article - articoli 26.436
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 684
selected - selezionate 0
volume - volumi 450
Totale 55.350
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020931 0 0 0 0 0 138 137 191 170 134 73 88
2020/2021874 45 71 67 81 42 59 31 90 132 87 111 58
2021/20221.287 32 206 204 103 23 36 74 154 38 16 174 227
2022/2023763 204 17 4 59 150 115 2 76 83 4 39 10
2023/2024359 13 49 47 40 12 41 9 22 15 7 50 54
2024/2025813 2 74 97 74 532 34 0 0 0 0 0 0
Totale 8.009